Ironwood Pharmaceuticals, Inc. Class A Common Stock (I76)
XDUS
3.36
+0.02 (+0.60%)
Closed
Oct 8, 2026
Day's Range
3.223.36
52 wk Range
1.194.58
Financial Statements - I76 - Ironwood Pharmaceuticals, Inc. Class A Common Stock
Revenue
296.15M▼ 15.7%
Net Income
24.01M▲ 2629.2%Net Margin 8.1%
EBITDA
124.90M▲ 21.5%
Free Cash Flow
127.01M▲ 22.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 296.15M | 351.41M | 442.73M | 410.59M | 413.75M | 389.52M |
| Cost of Goods | - | - | - | 0 | 0 | 3.13M |
| Gross Profit | - | - | - | 410.59M | 413.75M | 386.38M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 118.75M | 95.71M | 168.33M | 250.33M | 232.21M | 158.32M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -20.06M | -1.95M | -1.11B | 182K | -1.13M | -21.48M |
| Pre Tax Income | 70.02M | 65.19M | -948.06M | 252.42M | 200.65M | 108.86M |
| Income Tax | 46M | 64.31M | 83.49M | 77.35M | -327.79M | 2.68M |
| Net Income | 24.01M | 880K | -1.03B | 175.06M | 528.44M | 106.17M |
| EPS Basic | 0.15 | 0.01 | -6.45 | 1.13 | 3.26 | 0.67 |
| EPS Diluted | 0.15 | 0.01 | -6.45 | 0.96 | 3.21 | 0.66 |
| Basic Shares Outstanding | 161.84M | 159.08M | 168.35M | 160.65M | 168.85M | 165.91M |
| Diluted Shares Outstanding | 161.84M | 159.08M | 168.35M | 160.65M | 168.85M | 165.91M |
| Ebit | 102.77M | 98.23M | -926.44M | 260.02M | 231.80M | 138.33M |
| Ebitda | 124.90M | 102.83M | 188.90M | 261.23M | 234.44M | 163.41M |
| Net Income Continuous Operations | 24.01M | 880K | -1.03B | 175.06M | 528.44M | 106.17M |
| Minority Interests | - | 0 | 29.32M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
